DataMEDS AI Reports Corexa Pharmacy’s First Commercial Sale of a Compounded Peptide
DataMEDS AI said its Corexa Pharmacy subsidiary completed its first commercial sale of one of six compounded peptides, while highlighting regulatory and operational uncertainties.
DataMEDS AI, Inc. (NASDAQ:MEDS) said on November 9, 2026, that its Corexa Pharmacy subsidiary completed its first commercial sale of one of six compounded peptides. The company said the dispensing process was carried out in accordance with the U.S. Health and Human Services’ Enforcement Discretion Policy.
The products are BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax. DataMEDS said the peptides were recommended by the FDA’s Pharmacy Compounding Advisory Committee at its July 23-24, 2026 meeting.
The company stated that the Six Peptides are compounded drugs, are not FDA-approved and have not been evaluated by the FDA for safety or efficacy.
Gerald Commissiong, Interim Co-CEO of DataMEDS, said Corexa Pharmacy had worked through the dispensing requirements associated with the Enforcement Discretion Policy. He said the company is developing its pricing model and intends to begin marketing the offering in a compliant manner in the very near future.
According to the company, compounded medications are prescribed individually for patients. DataMEDS said its marketing would therefore focus on physicians who prescribe the medications and can provide the required oversight.
#Pharmacy infrastructure and regulatory conditions
DataMEDS said it intends to use its pharmacy hub and distribution warehouse capabilities for the peptide business. The company also identified the ability to compound, dispense and distribute the products in compliance with the FDA’s enforcement discretion policy, Section 503A of the Federal Food, Drug, and Cosmetic Act and state pharmacy laws as an ongoing matter.
Required licensing for the pharmacy hub and distribution warehouse is also among the conditions identified by the company. DataMEDS said the FDA or HHS could change or withdraw the Enforcement Discretion Policy, while the FDA’s final decisions concerning the 503A bulks list remain relevant to the plans.
DataMEDS cited a Precedence Research estimate that the U.S. compounding pharmacy market is expected to grow from $18.02 billion in 2025 to over $31.77 billion by 2034. The company separately listed the accuracy of third-party market-size estimates among the uncertainties connected with its plans.
DataMEDS describes itself as a healthcare company combining health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform. Its Corexa Health subsidiary provides pharmacy dispensing and related services.
The company also owns Helomics Corporation, a commercial clinical molecular diagnostics laboratory in Pittsburgh, PA, focused on the ChemoFx® Assay chemotherapy selection diagnostics test. DataMEDS said its platforms are incorporated into the Health Lives Here mobile application from Tollo Health, LLC. Tollo Health commercialises medical foods and dietary supplements and develops biopharmaceutical candidates through TolloBio.
DataMEDS identified several factors that could affect its compounded peptide plans. These include compliance with federal and state requirements, changes to the Enforcement Discretion Policy, FDA decisions on the 503A bulks list, pricing and the timing of marketing to prescribing physicians.
The company also cited physician prescribing demand, market acceptance, reliance on third-party suppliers and partner pharmacies, the quality and availability of bulk drug substances, sterile-compounding compliance, adverse events and product liability.
Other matters identified by DataMEDS include competition from other compounding pharmacies and unregulated research-use-only products, required licensing, related-party arrangements with Tollo Health, Nasdaq listing compliance, liquidity, capital resources and the ability to fund operations. The company said actual results may differ materially from its forward-looking statements and cautioned readers not to place undue reliance on them.
DataMEDS AI, Inc. announced that its Corexa Pharmacy subsidiary had completed its first commercial sale of one of the Six Peptides under the U.S. Health and Human Services' Enforcement Discretion Policy. The company said the sale followed work to dispense the peptides in compliance with the policy.
DataMEDS AI, Inc. made the announcement on November 9, 2026. It concerned Corexa Pharmacy's first commercial sale of one of the Six Peptides under the Enforcement Discretion Policy.
The Six Peptides are BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax. The company said they are compounded drugs, are not FDA-approved and have not been evaluated by the FDA for safety or efficacy.
DataMEDS AI, Inc. said the sales are being made in accordance with the U.S. Health and Human Services' Enforcement Discretion Policy, following recommendations involving the FDA's Pharmacy Compounding Advisory Committee at its July 23-24, 2026 meeting. The company also referred to compliance with Section 503A of the Federal Food, Drug, and Cosmetic Act and state pharmacy laws.
DataMEDS AI, Inc. said it is currently working through its pricing model and intends to begin actively marketing the offering in a compliant fashion in the very near future. Gerald Commissiong, Interim Co-CEO, said the marketing will focus on physicians who prescribe the medications and can provide appropriate oversight, because compounded medications are prescribed on a one-to-one basis for individual patients.
Gerald Commissiong said DataMEDS AI, Inc. intends to bring its pharmacy hub and distribution warehouse capabilities to the fore after confirming that Corexa Pharmacy could dispense the Six Peptides in compliance with recent guidelines. The release also identifies required licensure for the pharmacy hub and distribution warehouse as a forward-looking matter.
DataMEDS AI, Inc. is a healthcare company that integrates health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform. Its Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, while the company also owns Helomics Corporation, a commercial clinical molecular diagnostics laboratory focused on the ChemoFx® Assay.
DataMEDS AI, Inc. shares trade on NASDAQ under the ticker symbol MEDS, written in the source as NASDAQ:MEDS.
DataMEDS AI, Inc. cited a Precedence Research estimate that the U.S. compounding pharmacy market is expected to grow from $18.02 billion in 2025 to over $31.77 billion by 2034. The release separately lists the accuracy of third-party market-size estimates among its forward-looking risks.
DataMEDS AI, Inc. said the FDA or HHS may change or withdraw the Enforcement Discretion Policy, and that the FDA's final decisions regarding the 503A bulks list remain relevant. The company also identified risks involving pricing and compliant marketing, physician demand and market acceptance, third-party suppliers and partner pharmacies, bulk drug substance quality and availability, sterile compounding, adverse events and product liability, competition, required licensing, related-party arrangements with Tollo Health, LLC, Nasdaq listing compliance, liquidity, capital resources and the ability to fund operations.
DataMEDS AI, Inc. said its EinsteinRx™ and PharmacyChain™ platforms are incorporated into the Health Lives Here mobile application from Tollo Health, LLC. Tollo Health commercialises proprietary medical foods and dietary supplements and, through TolloBio, develops biopharmaceutical candidates, while Corexa Health distributes select Tollo Health products under a wholesale distribution arrangement.
DataMEDS AI, Inc. said it is working through the pricing model and intends to begin actively marketing the offering in a compliant fashion in the very near future. The company also said its plans depend on compliance with the applicable policy and laws, and that future outcomes may be affected by changes to the policy, prescribing demand, market acceptance and other stated risks.